Moreover, the ratio of infiltrating immune-suppressive macrophages and CD8+ effector T cells has been shown to carry predictive value for the outcome of chemotherapy in BrC [6], indicating the crucial importance of the balance between immune suppression and activation in the tumor microenvironment for the clinical efficacy of currently applied chemotherapy regimens. The gene discussed is CD8A; the disease is neoplasm.